Thrombin based gelatin matrix and fibrin sealant mediated clot formation in the presence of clopidogrel.

Background: Platelet inhibitors are commonly used to reduce the risk of atherothrombotic events. The aim of this study was to determine the impact of platelet inhibitors, specifically clopidogrel and aspirin, on clot kinetics, strength, and/or structure during the use of thrombin based gelatin matrices and fibrin sealants.

Methods: Blood was collected and heparinized from donors on clopidogrel (and aspirin) and age matched control donors.

Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro.

This study analyzed the ability of fibrin gels to deliver added recombinant transforming growth factor beta-1 (TGF-beta1) in a controlled manner and biologically active form. First, the effects of the amount of TGF-beta1 on the release kinetics were analyzed using a single fibrin gel formulation (fibrinogen complex (FC) at 25 mg/mL, thrombin at 2 IU/mL). Then, the effects of FC and thrombin concentrations were analyzed.